On this page, you can update your details, access training courses, and find other helpful resources to support your business membership of Anaphylaxis UK.
Since our rebranding and new website in July 2022, we’ve already reached a staggering number of page views.
Our latest social media campaign reached over 650,000 unique people in 10 weeks with nearly 12,000 views on the campaign page and nearly 2,000 sign-ups to the campaign email.
Our Facebook page reaches 489,000 people and our organic post reach is over 72,500.
Our monthly newsletter has an open rate of over 56%.
Download the Anaphylaxis UK Business Member logos along with the Brand Guidelines. Please use the Brand Guidelines on how to correctly display the logos and link to the Anaphylaxis Homepage: https://www.anaphylaxis.org.uk/
The Anaphylaxis UK Business Member logos
The Anaphylaxis UK Brand Guidelines
Access training for you and colleagues here. The training courses are only available to Business Members.
Get the latest news. To feature news of your own, get in touch!
We are delighted to be launching our Bee and Wasp Venom Awareness Campaign for 2024, supported by an educational grant from ALK. The campaign will offer invaluable guidance on bee and wasp sting avoidance, recognising anaphylaxis symptoms, the steps to take in an emergency and information about venom immunotherapy.
Anaphylaxis UK is proud to be recognising our 30th anniversary this year… Three decades of unwavering support. To mark the anniversary, we’re launching our ’30 Reasons’ anniversary campaign to showcase the people and stories that motivate us to do what we do here at Anaphylaxis UK.
Acaster Lloyd Consulting are looking for participants to take part in a research study about caregivers’ and children’s Experiences of taking an oral peanut protein powder (immunotherapy) treatment or 2. Their thoughts about how an oral peanut protein powder (immunotherapy)
Aimmune Therapeutics’ PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy. The European Commission (EC) has approved PALFORZIA® for the treatment of peanut allergy, making it the first treatment for the condition. Produced by Aimmune
Allergy Therapeutics PLC – Sussex-based biotechnology firm focused on allergy vaccines – Initiates peanut allergy biomarker study with Imperial College London to confirm potential of novel peanut vaccine candidate. The study aims to evaluate the novel virus like particle based
Some of our Business Members are featured here.
Update your subscription details
Go nowUpdate your company details and logo
Go nowPlease complete the details below so we can set up your new account.